Jordan Jousma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jordan Jousma has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Sang-Bing Ong
Department of Pharmacology and Regenerative Medicine, Division of Cardiology College of Medicine University of Illinois Chicago Chicago Illinois USA
4 shared publications - Youjeong Kwon
Department of Pharmacology & Regenerative Medicine University of Illinois College of Medicine Chicago IL 60612 USA
3 shared publications - Anna Di Rienzo
Department of Human Genetics, University of Chicago
2 shared publications Gege Yan
Department of Pharmacology and Regenerative Medicine, University of Illinois College of Medicine, Chicago (G.Y., Z.H., Y.K., J.J., S.B.N., X.D., S.P., S.-G.O.).
2 shared publications- Gege Yan
Department of Pharmacology & Regenerative Medicine University of Illinois College of Medicine Chicago IL 60612 USA
2 shared publications - Olivia A. Gray
Department of Human Genetics, University of Chicago, Chicago, IL
2 shared publications
Latest Publications
- Open Access
- 23 November 2025
- Published by Wiley in Advanced Science
- Vol. 13 (7) , e06106
Targeting Adipose Tissue Function Protects Against Heart Failure with Preserved Ejection Fraction
This study seeks to develop a better understanding of how the targeting of adipose tissue (AT) can mediate outcomes in cardiac function. Obesity is highly prevalent among individuals with heart failure with preserved ejection fraction (HFpEF). While thermogenic AT helps counteract obesity‐related conditions, its impact on heart function in obesity‐related HFpEF is unclear. Using a “two‐hit” HFpEF model, the study evaluates the impact of thermogenic AT on cardiac function through pharmacological, surgical, and genetic interventions. Activation of thermogenic AT via the β3‐adrenergic receptor agonist CL‐316,243 (CL) improves cardiac function, protects against HFpEF‐induced remodeling, and enhances energy expenditure. Similarly, transplantation of AT from CL‐treated mice into wild‐type recipients confers cardioprotection. In contrast, genetic suppression of thermogenesis ( Adipoq ‐Cre; Prdm16 fl/fl ) abolishes CL's benefits, while genetic enhancement of thermogenic AT ( Ucp1 ‐Cre ERT2 ; Cdkn2a fl/fl ) improves cardiac structure and function. Mechanistically, AT thermogenesis is linked with significant alterations in the cardiac lipidome, as revealed by lipidomic analysis via LC/MS‐MS. These findings establish the adipose‐heart axis as a promising therapeutic target for obesity‐related HFpEF and cardiometabolic health.
- 23 November 2025
- Published by Wiley in Advanced Science
- Vol. 13 (7) , e06106
Open AccessTargeting Adipose Tissue Function Protects Against Heart Failure with Preserved Ejection Fraction
This study seeks to develop a better understanding of how the targeting of adipose tissue (AT) can mediate outcomes in cardiac function. Obesity is highly prevalent among individuals with heart failure with preserved ejection fraction (HFpEF). While thermogenic AT helps counteract obesity‐related conditions, its impact on heart function in obesity‐related HFpEF is unclear. Using a “two‐hit” HFpEF model, the study evaluates the impact of thermogenic AT on cardiac function through pharmacological, surgical, and genetic interventions. Activation of thermogenic AT via the β3‐adrenergic receptor agonist CL‐316,243 (CL) improves cardiac function, protects against HFpEF‐induced remodeling, and enhances energy expenditure. Similarly, transplantation of AT from CL‐treated mice into wild‐type recipients confers cardioprotection. In contrast, genetic suppression of thermogenesis ( Adipoq ‐Cre; Prdm16 fl/fl ) abolishes CL's benefits, while genetic enhancement of thermogenic AT ( Ucp1 ‐Cre ERT2 ; Cdkn2a fl/fl ) improves cardiac structure and function. Mechanistically, AT thermogenesis is linked with significant alterations in the cardiac lipidome, as revealed by lipidomic analysis via LC/MS‐MS. These findings establish the adipose‐heart axis as a promising therapeutic target for obesity‐related HFpEF and cardiometabolic health.
- Open Access
- 10 February 2025
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 21 (2) , e1011570
Transcriptomic analysis of iPSC-derived endothelium reveals adaptations to high altitude hypoxia in energy metabolism and inflammation
Tibetan adaptation to high-altitude hypoxia remains a classic example of Darwinian selection in humans. Amongst Tibetan populations, alleles in the EPAS1 gene - whose protein product, HIF-2α, is a central regulator of the hypoxia response - have repeatedly been shown to carry some of the strongest signals of positive selection in humans. However, selective sweep signals alone may only account for some of the phenotypes that differentiate high-altitude adapted populations from closely related lowlanders. Therefore, there is a pressing need to functionally probe adaptive alleles and their impact at both the locus-specific and genome-wide levels and across cell types to uncover the full range of beneficial traits. To this end, we established a library of induced pluripotent stem cells (iPSCs) derived from Tibetan and Han Chinese individuals, a robust model system allowing precise exploration of allelic effects on transcriptional responses, and we differentiated them into vascular endothelium. Using this system, we focus first on a hypoxia-dependent enhancer (ENH5) that contributes to the regulation of EPAS1 to investigate its locus-specific effects in endothelium. Then, to cast a wider net, we harness the same experimental system to compare the transcriptome of Tibetan and Han Chinese cells in hypoxia and find evidence that angiogenesis, energy metabolism and immune pathways differ between these two populations with different histories of long-term residence at high altitude. Coupled with evidence of polygenic adaptations targeting the same pathways, these results suggests that the observed transcriptional differences between the two populations were shaped by natural selection.
- 10 February 2025
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 21 (2) , e1011570
Open AccessTranscriptomic analysis of iPSC-derived endothelium reveals adaptations to high altitude hypoxia in energy metabolism and inflammation
Tibetan adaptation to high-altitude hypoxia remains a classic example of Darwinian selection in humans. Amongst Tibetan populations, alleles in the EPAS1 gene - whose protein product, HIF-2α, is a central regulator of the hypoxia response - have repeatedly been shown to carry some of the strongest signals of positive selection in humans. However, selective sweep signals alone may only account for some of the phenotypes that differentiate high-altitude adapted populations from closely related lowlanders. Therefore, there is a pressing need to functionally probe adaptive alleles and their impact at both the locus-specific and genome-wide levels and across cell types to uncover the full range of beneficial traits. To this end, we established a library of induced pluripotent stem cells (iPSCs) derived from Tibetan and Han Chinese individuals, a robust model system allowing precise exploration of allelic effects on transcriptional responses, and we differentiated them into vascular endothelium. Using this system, we focus first on a hypoxia-dependent enhancer (ENH5) that contributes to the regulation of EPAS1 to investigate its locus-specific effects in endothelium. Then, to cast a wider net, we harness the same experimental system to compare the transcriptome of Tibetan and Han Chinese cells in hypoxia and find evidence that angiogenesis, energy metabolism and immune pathways differ between these two populations with different histories of long-term residence at high altitude. Coupled with evidence of polygenic adaptations targeting the same pathways, these results suggests that the observed transcriptional differences between the two populations were shaped by natural selection.
- 1 March 2024
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 134 (5) , 482-501
Integrated Stress Response Potentiates Ponatinib-Induced Cardiotoxicity
BACKGROUND: Mitochondrial dysfunction is a primary driver of cardiac contractile failure; yet, the cross talk between mitochondrial energetics and signaling regulation remains obscure. Ponatinib, a tyrosine kinase inhibitor used to treat chronic myeloid leukemia, is among the most cardiotoxic tyrosine kinase inhibitors and causes mitochondrial dysfunction. Whether ponatinib-induced mitochondrial dysfunction triggers the integrated stress response (ISR) to induce ponatinib-induced cardiotoxicity remains to be determined. METHODS: Using human induced pluripotent stem cells–derived cardiomyocytes and a recently developed mouse model of ponatinib-induced cardiotoxicity, we performed proteomic analysis, molecular and biochemical assays to investigate the relationship between ponatinib-induced mitochondrial stress and ISR and their role in promoting ponatinib-induced cardiotoxicity. RESULTS: Proteomic analysis revealed that ponatinib activated the ISR in cardiac cells. We identified GCN2 (general control nonderepressible 2) as the eIF2α (eukaryotic translation initiation factor 2α) kinase responsible for relaying mitochondrial stress signals to trigger the primary ISR effector—ATF4 (activating transcription factor 4), upon ponatinib exposure. Mechanistically, ponatinib treatment exerted inhibitory effects on ATP synthase activity and reduced its expression levels resulting in ATP deficits. Perturbed mitochondrial function resulting in ATP deficits then acts as a trigger of GCN2-mediated ISR activation, effects that were negated by nicotinamide mononucleotide, an NAD + precursor, supplementation. Genetic inhibition of ATP synthase also activated GCN2. Interestingly, we showed that the decreased abundance of ATP also facilitated direct binding of ponatinib to GCN2, unexpectedly causing its activation most likely because of a conformational change in its structure. Importantly, administering an ISR inhibitor protected human induced pluripotent stem cell–derived cardiomyocytes against ponatinib. Ponatinib-treated mice also exhibited reduced cardiac function, effects that were attenuated upon systemic ISRIB administration. Importantly, ISRIB does not affect the antitumor effects of ponatinib in vitro. CONCLUSIONS: Neutralizing ISR hyperactivation could prevent or reverse ponatinib-induced cardiotoxicity. The findings that compromised ATP production potentiates GCN2-mediated ISR activation have broad implications across various cardiac diseases. Our results also highlight an unanticipated role of ponatinib in causing direct activation of a kinase target despite its role as an ATP-competitive kinase inhibitor.
- 1 March 2024
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 134 (5) , 482-501
Integrated Stress Response Potentiates Ponatinib-Induced Cardiotoxicity
BACKGROUND: Mitochondrial dysfunction is a primary driver of cardiac contractile failure; yet, the cross talk between mitochondrial energetics and signaling regulation remains obscure. Ponatinib, a tyrosine kinase inhibitor used to treat chronic myeloid leukemia, is among the most cardiotoxic tyrosine kinase inhibitors and causes mitochondrial dysfunction. Whether ponatinib-induced mitochondrial dysfunction triggers the integrated stress response (ISR) to induce ponatinib-induced cardiotoxicity remains to be determined. METHODS: Using human induced pluripotent stem cells–derived cardiomyocytes and a recently developed mouse model of ponatinib-induced cardiotoxicity, we performed proteomic analysis, molecular and biochemical assays to investigate the relationship between ponatinib-induced mitochondrial stress and ISR and their role in promoting ponatinib-induced cardiotoxicity. RESULTS: Proteomic analysis revealed that ponatinib activated the ISR in cardiac cells. We identified GCN2 (general control nonderepressible 2) as the eIF2α (eukaryotic translation initiation factor 2α) kinase responsible for relaying mitochondrial stress signals to trigger the primary ISR effector—ATF4 (activating transcription factor 4), upon ponatinib exposure. Mechanistically, ponatinib treatment exerted inhibitory effects on ATP synthase activity and reduced its expression levels resulting in ATP deficits. Perturbed mitochondrial function resulting in ATP deficits then acts as a trigger of GCN2-mediated ISR activation, effects that were negated by nicotinamide mononucleotide, an NAD + precursor, supplementation. Genetic inhibition of ATP synthase also activated GCN2. Interestingly, we showed that the decreased abundance of ATP also facilitated direct binding of ponatinib to GCN2, unexpectedly causing its activation most likely because of a conformational change in its structure. Importantly, administering an ISR inhibitor protected human induced pluripotent stem cell–derived cardiomyocytes against ponatinib. Ponatinib-treated mice also exhibited reduced cardiac function, effects that were attenuated upon systemic ISRIB administration. Importantly, ISRIB does not affect the antitumor effects of ponatinib in vitro. CONCLUSIONS: Neutralizing ISR hyperactivation could prevent or reverse ponatinib-induced cardiotoxicity. The findings that compromised ATP production potentiates GCN2-mediated ISR activation have broad implications across various cardiac diseases. Our results also highlight an unanticipated role of ponatinib in causing direct activation of a kinase target despite its role as an ATP-competitive kinase inhibitor.
- Open Access
- 19 July 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-15
Nuclear translocation of mitochondrial dehydrogenases as an adaptive cardioprotective mechanism
Chemotherapy-induced cardiac damage remains a leading cause of death amongst cancer survivors. Anthracycline-induced cardiotoxicity is mediated by severe mitochondrial injury, but little is known about the mechanisms by which cardiomyocytes adaptively respond to the injury. We observed the translocation of selected mitochondrial tricarboxylic acid (TCA) cycle dehydrogenases to the nucleus as an adaptive stress response to anthracycline-cardiotoxicity in human induced pluripotent stem cell-derived cardiomyocytes and in vivo. The expression of nuclear-targeted mitochondrial dehydrogenases shifts the nuclear metabolic milieu to maintain their function both in vitro and in vivo. This protective effect is mediated by two parallel pathways: metabolite-induced chromatin accessibility and AMP-kinase (AMPK) signaling. The extent of chemotherapy-induced cardiac damage thus reflects a balance between mitochondrial injury and the protective response initiated by the nuclear pool of mitochondrial dehydrogenases. Our study identifies nuclear translocation of mitochondrial dehydrogenases as an endogenous adaptive mechanism that can be leveraged to attenuate cardiomyocyte injury.
- 19 July 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-15
Open AccessNuclear translocation of mitochondrial dehydrogenases as an adaptive cardioprotective mechanism
Chemotherapy-induced cardiac damage remains a leading cause of death amongst cancer survivors. Anthracycline-induced cardiotoxicity is mediated by severe mitochondrial injury, but little is known about the mechanisms by which cardiomyocytes adaptively respond to the injury. We observed the translocation of selected mitochondrial tricarboxylic acid (TCA) cycle dehydrogenases to the nucleus as an adaptive stress response to anthracycline-cardiotoxicity in human induced pluripotent stem cell-derived cardiomyocytes and in vivo. The expression of nuclear-targeted mitochondrial dehydrogenases shifts the nuclear metabolic milieu to maintain their function both in vitro and in vivo. This protective effect is mediated by two parallel pathways: metabolite-induced chromatin accessibility and AMP-kinase (AMPK) signaling. The extent of chemotherapy-induced cardiac damage thus reflects a balance between mitochondrial injury and the protective response initiated by the nuclear pool of mitochondrial dehydrogenases. Our study identifies nuclear translocation of mitochondrial dehydrogenases as an endogenous adaptive mechanism that can be leveraged to attenuate cardiomyocyte injury.
- Open Access
- 23 November 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (47) , eade1942
A pleiotropic hypoxia-sensitive EPAS1 enhancer is disrupted by adaptive alleles in Tibetans
In Tibetans, noncoding alleles in EPAS1 —whose protein product hypoxia-inducible factor 2α (HIF-2α) drives the response to hypoxia—carry strong signatures of positive selection; however, their functional mechanism has not been systematically examined. Here, we report that high-altitude alleles disrupt the activity of four EPAS1 enhancers in one or more cell types. We further characterize one enhancer (ENH5) whose activity is both allele specific and hypoxia dependent. Deletion of ENH5 results in down-regulation of EPAS1 and HIF-2α targets in acute hypoxia and in a blunting of the transcriptional response to sustained hypoxia. Deletion of ENH5 in mice results in dysregulation of gene expression across multiple tissues. We propose that pleiotropic adaptive effects of the Tibetan alleles in EPAS1 underlie the strong selective signal at this gene.
- 23 November 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (47) , eade1942
Open AccessA pleiotropic hypoxia-sensitive EPAS1 enhancer is disrupted by adaptive alleles in Tibetans
In Tibetans, noncoding alleles in EPAS1 —whose protein product hypoxia-inducible factor 2α (HIF-2α) drives the response to hypoxia—carry strong signatures of positive selection; however, their functional mechanism has not been systematically examined. Here, we report that high-altitude alleles disrupt the activity of four EPAS1 enhancers in one or more cell types. We further characterize one enhancer (ENH5) whose activity is both allele specific and hypoxia dependent. Deletion of ENH5 results in down-regulation of EPAS1 and HIF-2α targets in acute hypoxia and in a blunting of the transcriptional response to sustained hypoxia. Deletion of ENH5 in mice results in dysregulation of gene expression across multiple tissues. We propose that pleiotropic adaptive effects of the Tibetan alleles in EPAS1 underlie the strong selective signal at this gene.
- 31 October 2022
- Published by Taylor & Francis in Epigenomics
- Vol. 14 (19) , 1139-1155
Alteration of the N 6 -Methyladenosine Epitranscriptomic Profile in Synthetic Phthalate-Treated Human Induced Pluripotent Stem Cell-Derived Endothelial Cells
Background: This study aimed to characterize the N6-methyladenosine epitranscriptomic profile induced by mono(2-ethylhexyl) phthalate (MEHP) exposure using a human-induced pluripotent stem cell-der... Plain language summary Synthetic phthalates, such as mono(2-ethyhexyl) phthalate, have long been recognized as environmental toxins. What effect these compounds have on endothelial cells remains po...
- 31 October 2022
- Published by Taylor & Francis in Epigenomics
- Vol. 14 (19) , 1139-1155
Alteration of the N 6 -Methyladenosine Epitranscriptomic Profile in Synthetic Phthalate-Treated Human Induced Pluripotent Stem Cell-Derived Endothelial Cells
Background: This study aimed to characterize the N6-methyladenosine epitranscriptomic profile induced by mono(2-ethylhexyl) phthalate (MEHP) exposure using a human-induced pluripotent stem cell-der... Plain language summary Synthetic phthalates, such as mono(2-ethyhexyl) phthalate, have long been recognized as environmental toxins. What effect these compounds have on endothelial cells remains po...